Clinical trials for Pancreatic cancer

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Pancreatic cancer. For all clinical trials, go to clinical trials search

This list shows clinical trials for Pancreatic cancer

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Pancreatic cancer
Title Recruitment status Location
A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Brazil
A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Bulgaria
A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Chile
A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER China
A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Colombia
A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Czech Republic
A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Georgia
A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Germany
A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Greece
A PROSPECTIVE, MULTICENTER, DOUBLE-RANDOMISED, DOUBLE-BLIND, 2-PARALLEL GROUPS, PHASE 3 STUDY TO COMPARE AS FIRST LINE THERAPY EFFICACY AND SAFETY OF MASITINIB IN COMBINATION WITH GEMCITABINE, TO GEMCITABINE IN COMBINATION WITH PLACEBO, FOLLOWED AS SECOND LINE TREATMENT BY MASITINIB IN COMBINATION WITH FOLFIRI 3 VERSUS PLACEBO IN COMBINATION WITH FOLFIRI 3 IN THE TREATMENT OF PATIENTS WITH NON RESECTABLE LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Hungary

Page last reviewed:

Next review due: